Investment Rating - The report maintains a "Buy" rating for the company [2][5] Core Views - The company has demonstrated significant growth potential, particularly in the functional sugar sector, with a reported revenue of RMB 1.15 billion in 2024, representing a year-on-year increase of 32.64% [4][8] - The gross profit margin has improved, reaching 33.65% in 2024, up 0.92 percentage points year-on-year, and further increasing to 39.74% in Q1 2025, up 5.99 percentage points year-on-year [8][11] - The company is expected to continue its growth trajectory with projected earnings per share (EPS) of RMB 1.05, RMB 1.34, and RMB 1.63 for 2025, 2026, and 2027 respectively, corresponding to price-to-earnings (PE) ratios of 25.8, 20.2, and 16.6 [5][7] Financial Performance Summary - In 2024, the company achieved total revenue of RMB 1,151.65 million, with a net profit of RMB 245.60 million, reflecting a growth rate of 27.26% compared to 2023 [9] - The fourth quarter of 2024 saw a revenue of RMB 331.26 million, a year-on-year increase of 54.46%, with a net profit of RMB 63.01 million, up 21.97% year-on-year [10] - For Q1 2025, the company reported revenue of RMB 313.30 million, a 24.27% increase year-on-year, and a net profit of RMB 81.42 million, up 52.06% year-on-year [11] Growth Drivers - The company is set to benefit from the full production of new projects, including a soluble dietary fiber project and a crystallized sugar project, which are expected to enhance its production capacity and profitability [8][9] - The demand for dietary fibers, prebiotics, and healthy sweeteners is anticipated to drive revenue growth, with dietary fiber revenue expected to grow over 40% in 2024 [8][9] - The company is actively expanding its product portfolio, with plans to launch new products such as isomaltulose and crystallized fructose in 2024, which are expected to contribute to revenue growth [8][9]

大消费概念持续活跃 丽人丽妆3连板 智通财经5月19日电，午后大消费概念持续活跃，医美、宠物经济方向领涨，丽人丽妆走出3连板，拉芳 家化、源飞宠物涨停，天元宠物、锦波生物、百龙创园、路斯股份股价创出历史新高。消息面上，据粤 开证券统计，国内消费医疗对应万亿级市场规模。医美领域市场规模预计2025年达到3529亿元。 ...

证券代码：605016 证券简称：百龙创园 公告编号：2025- 024 山东百龙创园生物科技股份有限公司 关于上海全资子公司取得营业执照的公告 名称：上海百龙创园生物科技有限公司 统一社会信用代码：91310112MAEKGANE6A 类型：有限责任公司（自然人投资或控股的法人独资） 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 山东百龙创园生物科技股份有限公司（以下简称"公司"）于 2025 年 4 月 29 日 召开了第三届董事会第十五次会议，审议通过《关于对外投资设立上海全资子公司的 议案》，拟以自有资金的方式在上海投资设立全资子公司上海百龙创园生物科技有限 公司（具体内容详见公司 2025 年 4 月 30 日披露的《关于对外投资设立上海全资子公 司的公告》2025-019）。 经上海市闵行区市场监督管理局核准，上海百龙创园生物科技有限公司已完成工 商注册登记，并于近日取得了营业执照，具体登记信息如下： 住所：上海市闵行区绍虹路 99 号 209 室 法定代表人：崔宏宇 注册资本：人民币 1000 万元整 成 ...

山东百龙创园生物科技股份有限公司 上市公司名称：山东百龙创园生物科技股份有限公司 股票上市地点：上海证券交易所 股票简称：百龙创园 通讯地址：河北省邯郸市武安市**** 股份变动性质：持股比例减少 签署日期：2025 年 5 月 14 日 信息披露义务人声明 股票代码：605016 信息披露义务人一：青岛恩复开金创业投资基金合伙企业（有限合伙） 注册地址：山东省青岛市平度市太原路 17 号山东财经大学平度创新创业园 A 栋 825 室 通讯地址：山东省青岛市平度市太原路 17 号山东财经大学平度创新创业园 A 栋 825 室 信息披露义务人二：嘉兴恩复开金投资合伙企业（有限合伙） 注册地址：浙江省嘉兴市南湖区南江路 1856 号基金小镇 3 号楼 105 室-63 通讯地址：浙江省嘉兴市南湖区南江路 1856 号基金小镇 3 号楼 105 室-63 信息披露义务人三：郭恩元 住址：河北省邯郸市武安市**** 本部分所述词语或简称与本报告书"释义"所述词语或简称具有相同含义。 （一）信息披露义务人依据《中华人民共和国公司法》、《中华人民共和 国证券法》、《上市公司收购管理办法》、《公开发行证券的公司信息披露内 ...

山东百龙创园生物科技股份有限公司 简式权益变动报告书 上市公司名称：山东百龙创园生物科技股份有限公司 股票上市地点：上海证券交易所 股票简称：百龙创园 股票代码：605016 信息披露义务人一：青岛恩复开金创业投资基金合伙企业（有限合伙） 注册地址：山东省青岛市平度市太原路 17 号山东财经大学平度创新创业园 A 栋 825 室 通讯地址：山东省青岛市平度市太原路 17 号山东财经大学平度创新创业园 A 栋 825 室 信息披露义务人二：嘉兴恩复开金投资合伙企业（有限合伙） 注册地址：浙江省嘉兴市南湖区南江路 1856 号基金小镇 3 号楼 105 室-63 通讯地址：浙江省嘉兴市南湖区南江路 1856 号基金小镇 3 号楼 105 室-63 （一）信息披露义务人依据《中华人民共和国公司法》、《中华人民共和 国证券法》、《上市公司收购管理办法》、《公开发行证券的公司信息披露内 容与格式准则第 15 号——权益变动报告书》及其他相关的法律、法规编写本报 告书。 信息披露义务人三：郭恩元 住址：河北省邯郸市武安市**** 通讯地址：河北省邯郸市武安市**** 股份变动性质：持股比例减少 签署日期：2025 年 5 ...

| 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 002688 | 金河生物 | 0.00 | 6.48 | -4498.31 | | 600108 | 亚盛集团 | -2.01 | 3.36 | -2520.01 | | 002286 | 保龄宝 | -6.11 | 14.36 | -2292.62 | | 301206 | 三元生物 | -1.46 | 5.27 | -1829.27 | | 600866 | 星湖科技 | 1.09 | 2.49 | -1239.51 | | 600783 | 鲁信创投 | 1.34 | 0.66 | -737.61 | | 002078 | 太阳纸业 | 0.14 | 0.57 | -629.24 | | 600873 | 梅花生物 | 0.00 | 0.83 | -594.99 | | 300138 | 晨光生物 | -2.34 | 4.50 | -438.70 | | 605077 | 华康股份 | -1.96 | 1.41 | -305.92 | | 0 ...

证券代码：605016 证券简称：百龙创园 公告编号：2025-023 特此公告！ 山东百龙创园生物科技股份有限公司 山东百龙创园生物科技股份有限公司董事会 关于参加 2025 年山东辖区上市公司投资者 网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为进一步加强与投资者的互动交流，山东百龙创园生物科技股份有限公司 （以下简称"公司"）将参加由山东证监局、山东上市公司协会与深圳市全景网 络有限公司联合举办的"2025 年山东辖区上市公司投资者网上集体接待日活动"， 现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景 路演 APP,参与本次互动交流。活动时间为 2025 年 5 月 15 日（周四）15:00-16:30。 届时公司高管将在线就公司 2024 年度业绩、公司治理、发展战略、 经营状况、 融资计划、股权激励和可持续发展等投资者关心的问题，与投资者进行沟通与交 流 ...

Summary of Conference Call on D-Allulose Industry Overview - The focus is on the D-Allulose market, a new segment within the sugar substitute industry, which is gaining traction due to recent policy support and health trends [1][2]. Key Points and Arguments 1. **Policy Support**: The Ministry of Commerce and the National Health Commission, along with 12 other departments, issued a notice promoting healthy consumption, emphasizing dietary guidance for patients with hypertension, type 2 diabetes, hyperlipidemia, and obesity. This highlights the importance of health-focused food products like D-Allulose [1]. 2. **Health Benefits**: D-Allulose is recognized for its potential to lower blood pressure and lipid levels, as well as its role in preventing type 2 diabetes, aligning with the government's health initiatives [1]. 3. **Regulatory Approval**: The National Health Commission completed a public consultation on D-Allulose on April 20, marking its path towards compliance and potential market entry [1]. 4. **Market Potential**: D-Allulose is expected to replace existing sugar substitutes in beverages and food, indicating a significant market opportunity. The global approval history of D-Allulose spans 14 years, with countries like the USA, Japan, Mexico, Canada, South Korea, and Australia recognizing it as a food ingredient [2]. 5. **GRAS Status**: D-Allulose is classified as GRAS (Generally Recognized As Safe) by FEMA, allowing its use in beverages and dairy products, further enhancing its marketability [2]. 6. **Health Advantages**: In addition to its sweetening properties, D-Allulose offers benefits such as promoting the Maillard reaction, lowering blood sugar and lipid levels, aiding liver detoxification, and preventing obesity and type 2 diabetes [2]. 7. **Company Developments**: - **Baolingbao**: Currently constructing a 30,000-ton D-Allulose project, which will be actively promoted for consumer sales once approved for domestic use [3]. - **Bailong Chuangyuan**: Has a crystallized sugar project with an annual capacity of 15,000 tons, which can produce 5,000 tons of D-Allulose [3]. Additional Important Information - D-Allulose is positioned as a new star among sweeteners, with no reported side effects and the ability to release GLP-1, which can combat obesity and diabetes [2]. - Companies to watch in this sector include Bailong Chuangyuan, Baolingbao, Sanyuan Biological, and Huakang Co. [2].

Summary of Conference Call Records Industry Overview - The records focus on the **sugar substitute industry**, specifically the emerging segment of **D-Allulose** as a health-oriented sweetener. The industry is experiencing significant regulatory changes and market opportunities due to new health consumption policies in China [1][2]. Key Points and Arguments - The **Ministry of Commerce and the National Health Commission** of China, along with 12 other departments, issued a notice on promoting health consumption, emphasizing the need to improve healthy dietary consumption levels. This includes guidance for healthcare institutions to provide dietary and exercise advice for patients with hypertension, type 2 diabetes, hyperlipidemia, and obesity [1][2]. - The notice highlights the importance of **food health products**, indicating a high level of attention towards health-oriented sweeteners like **D-Allulose**, which has benefits in lowering blood pressure, reducing lipids, and preventing type 2 diabetes [1][2]. - D-Allulose is on the verge of regulatory approval in China, marking a significant milestone for the domestic sugar substitute market. The product has a long history of approval in other countries, including the United States, Japan, Mexico, Canada, South Korea, and Australia/New Zealand [3]. - D-Allulose is recognized as a **GRAS (Generally Recognized As Safe)** product by FEMA, allowing its use in beverages and dairy products. Canada has also approved it as a natural health product ingredient [3]. - The product not only shares the advantages of **Erythritol** but also promotes the Maillard reaction, lowers blood sugar and lipids, aids liver detoxification, and helps prevent obesity and type 2 diabetes [3]. Company Insights - **Baolingbao** is currently constructing a **30,000-ton D-Allulose project**, which is in the building phase. The company plans to actively promote sales to consumers once D-Allulose is approved for use in China [4]. - **Bailong Chuangyuan** has a **15,000-ton crystalline sugar project** that can produce **5,000 tons of D-Allulose** [4]. Additional Important Content - The records suggest that D-Allulose is emerging as a new star among sweeteners, with no reported side effects. It has similar effects to GLP-1 (glucagon-like peptide-1), which can help combat obesity and diabetes [3]. - The market potential for D-Allulose is vast, as it is expected to replace existing sugar substitutes in beverages and food products, indicating a significant growth trend in the industry [3]. Conclusion - The regulatory environment is becoming increasingly favorable for D-Allulose, positioning it as a key player in the health-oriented sweetener market. Companies like Baolingbao and Bailong Chuangyuan are poised to capitalize on this trend, potentially leading to substantial market growth and investment opportunities in the sector [3][4].

A股代糖概念板块震荡上升，百龙创园封板涨停，亚盛集团涨超4%，金禾实业涨近4%，红棉股份、三 元生物等跟涨。 ...